Astel­las en­lists Pep­tiDream in search for pro­tein de­graders as it looks to act fast in hot field

In its lat­est push in­to the field of tar­get­ed pro­tein degra­da­tion, Astel­las has tapped fel­low Japan­ese com­pa­ny Pep­tiDream for a re­search col­lab­o­ra­tion and li­cens­ing deal.

Astel­las is pay­ing $21 mil­lion (¥3 bil­lion) up­front to kick-start dis­cov­ery work on two tar­gets it se­lects. It has the op­tion to add three more tar­gets to the deal, with $150 mil­lion (¥20.6 bil­lion) per tar­get on the ta­ble in the form of mile­stones in ad­di­tion to roy­al­ties.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER